These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11991219)

  • 21. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
    Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
    Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydrochlorothiazide and spironolactone in hypertension.
    Schrijver G; Weinberger MH
    Clin Pharmacol Ther; 1979 Jan; 25(1):33-42. PubMed ID: 363334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    Williams GH; Burgess E; Kolloch RE; Ruilope LM; Niegowska J; Kipnes MS; Roniker B; Patrick JL; Krause SL
    Am J Cardiol; 2004 Apr; 93(8):990-6. PubMed ID: 15081441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?
    Plouin PF; Battaglia C; Alhenc-Gélas F; Corvol P
    Am J Hypertens; 1991 Apr; 4(4 Pt 1):356-62. PubMed ID: 2059395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension].
    Naudzhunas A; Bagdonas G; Yankauskene L; Kazanavichus G
    Ter Arkh; 2006; 78(2):61-4. PubMed ID: 16613101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of blood pressure and the renin-angiotensin-aldosterone axis to hypotensive therapy: comparison of propranolol with spironolactone.
    Espiner EA; Mansfield H; Miles K
    N Z Med J; 1977 Sep; 86(595):216-9. PubMed ID: 343004
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients.
    Menon DV; Arbique D; Wang Z; Adams-Huet B; Auchus RJ; Vongpatanasin W
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1361-6. PubMed ID: 19158191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.
    Newton-Cheh C; Guo CY; Gona P; Larson MG; Benjamin EJ; Wang TJ; Kathiresan S; O'Donnell CJ; Musone SL; Camargo AL; Drake JA; Levy D; Hirschhorn JN; Vasan RS
    Hypertension; 2007 Apr; 49(4):846-56. PubMed ID: 17296870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerance of spironolactone in essential hypertension.
    Jeunemaitre X; Chatellier G; Kreft-Jais C; Charru A; DeVries C; Plouin PF; Corvol P; Menard J
    Am J Cardiol; 1987 Oct; 60(10):820-5. PubMed ID: 3661395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data.
    Shuey M; Perkins B; Nian H; Yu C; Luther JM; Brown N
    BMJ Open; 2020 May; 10(5):e033100. PubMed ID: 32461291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.
    Rosa J; Widimský P; Waldauf P; Lambert L; Zelinka T; Táborský M; Branny M; Toušek P; Petrák O; Čurila K; Bednář F; Holaj R; Štrauch B; Václavík J; Nykl I; Krátká Z; Kociánová E; Jiravský O; Rappová G; Indra T; Widimský J
    Hypertension; 2016 Feb; 67(2):397-403. PubMed ID: 26693818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
    Lin M; Heizati M; Wang L; Nurula M; Yang Z; Wang Z; Abudoyreyimu R; Wu Z; Li N
    Blood Press; 2021 Jun; 30(3):145-153. PubMed ID: 33682538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasma Renin Activity and Potential of Indapamide Retard to Improve Control of Hypertension].
    Kobalava ZhD; Kotovskaia IuV; Kravtsova OA
    Kardiologiia; 2015; 55(2):21-6. PubMed ID: 26164984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refractory hypertension: definition, prevalence, and patient characteristics.
    Acelajado MC; Pisoni R; Dudenbostel T; Dell'Italia LJ; Cartmill F; Zhang B; Cofield SS; Oparil S; Calhoun DA
    J Clin Hypertens (Greenwich); 2012 Jan; 14(1):7-12. PubMed ID: 22235818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.